Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Pharmacological exposures may precipitate craniosynostosis through targeted stem cell depletion.

Emily Durham | R Nicole Howie | Nicholas Larson | Amanda LaRue | James Cray
Stem cell research | 2019

The Centers for Disease Control and Prevention, National Birth Defects Study suggests that environmental exposures including maternal thyroid diseases, maternal nicotine use, and use of selective serotonin reuptake inhibitors (SSRIs) may exacerbate incidence and or severity of craniofacial abnormalities including craniosynostosis. Premature fusion of a suture(s) of the skull defines the birth defect craniosynostosis which occurs in 1:1800-2500 births. A proposed mechanism of craniosynostosis is the disruption of proliferation and differentiation of cells in the perisutural area. Here, we hypothesize that pharmacological exposures including excess thyroid hormone, nicotine, and SSRIs lead to an alteration of stem cells within the sutures resulting in premature fusion. In utero exposure to nicotine and citalopram (SSRI) increased the risk of premature suture fusion in a wild-type murine model. Gli1+ stem cells were reduced, stem cell populations were depleted, and homeostasis of the suture mesenchyme was altered with exposure. Thus, although these pharmacological exposures can deplete calvarial stem cell populations leading to craniosynostosis, depletion of stem cells is not a unifying mechanism for pharmacological exposure associated craniosynostosis.

Pubmed ID: 31415959

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDCR NIH HHS, United States
    Id: T32 DE017551
  • Agency: NIGMS NIH HHS, United States
    Id: P30 GM103331
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000062
  • Agency: BLRD VA, United States
    Id: I01 BX000333
  • Agency: NIA NIH HHS, United States
    Id: P01 AG036675
  • Agency: NIDCR NIH HHS, United States
    Id: R03 DE023350
  • Agency: NIDCR NIH HHS, United States
    Id: F31 DE026684
  • Agency: NIDCR NIH HHS, United States
    Id: R03 DE026192

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Novus Biologicals (tool)

RRID:SCR_004286

Commercial antibody vendor which supplies antibodies and other products to life science researchers.

View all literature mentions

FlowJo (tool)

RRID:SCR_008520

Software for single-cell flow cytometry analysis. Its functions include management, display, manipulation, analysis and publication of the data stream produced by flow and mass cytometers.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions